Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)-Reference-Cited by-同舟云学术

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)

Published:2018-09 Issue:9 Volume:13 Page:1393-1399
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Gadgeel Shirish M.,Pennell Nathan A.,Fidler Mary Jo,Halmos Balazs,Bonomi Philip,Stevenson James,Schneider Bryan,Sukari Ammar,Ventimiglia Jaclyn,Chen Wei,Galasso Cathy,Wozniak Antoinette,Boerner Julie,Kalemkerian Gregory P.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference20 articles.

1. American Cancer Society. Key statistics for small cell lung cancer. https://www.cancer.org/cancer/small-cell-lung-cancer/about/key-statistics.html. Accessed April 2, 2018.

2. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II study- CALGB 30504 (Alliance);Ready;J Clin Oncol,2015

3. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next?;Shin;Curr Opin Immunol,2015

4. PD-1 blockade in advanced NSCLC: a focus on pembrolizumab;Meng;Cancer Treat Rev,2018

5. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer;Bracci;Cell Death Differ,2014

Cited by 168 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer;Cell & Bioscience;2024-09-12

2. Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer;Cancer Research Communications;2024-09-01

3. Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities;Experimental Hematology & Oncology;2024-08-05

4. Effectiveness and safety of anlotinib plus anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies as maintenance therapy after first-line chemotherapy combined with anti-PD-1/PD-L1 antibodies in extensive-stage small cell lung cancer: a real-world study;Journal of Thoracic Disease;2024-07

5. Extensive-stage small-cell lung cancer in patients receiving atezolizumab plus carboplatin–etoposide: stratification of outcome based on a composite score that combines gene expression profiling and immune characterization of microenvironment;Journal for ImmunoTherapy of Cancer;2024-07